GlycoMimetics (NASDAQ:GLYC) Earns Sell Rating from Analysts at StockNews.com

Posted by ABMN Staff on Jan 27th, 2025

Equities research analysts at StockNews.com began coverage on shares of GlycoMimetics (NASDAQ:GLYC – Get Free Report) in a note issued to investors on Saturday. The firm set a “sell” rating on the biotechnology company’s stock.

GlycoMimetics Stock Up 0.9 %

Shares of NASDAQ:GLYC opened at $0.27 on Friday. GlycoMimetics has a 12 month low of $0.14 and a 12 month high of $3.50. The company has a 50-day moving average price of $0.28 and a 200-day moving average price of $0.24.

Institutional Investors Weigh In On GlycoMimetics

A hedge fund recently raised its stake in GlycoMimetics stock. Renaissance Technologies LLC lifted its holdings in shares of GlycoMimetics, Inc. (NASDAQ:GLYC – Free Report) by 483.5% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 826,851 shares of the biotechnology company’s stock after acquiring an additional 685,151 shares during the quarter. Renaissance Technologies LLC owned approximately 1.28% of GlycoMimetics worth $233,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 75.19% of the company’s stock.

GlycoMimetics Company Profile

(Get Free Report)

GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.